New drug combo aims to tackle tough leukemia
NCT ID NCT07303660
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find a safe dose and check for early signs that the combination might help control the disease. Participants will take both drugs by mouth or injection over 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lonitoclax and azacitidine
- What this could lead to
- If it works, this could point toward a new treatment option for people with acute myeloid leukemia that has come back or not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1b) study with only 66 participants, focused mainly on safety and dosing. It is too soon to know if the combination will be effective or safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?